Cycle-length mapping with OPTRELL for non-paroxysmal atrial fibrillation
Official title: A Prospective Study on the Cycle-Length Mapping Using the OPTRELL™ Mapping Catheter in Patients With Non-paroxysmal Atrial Fibrillation
Run by Taipei Veterans General Hospital, Taiwan · NCT06960252 · Data updated 2026-11-12
This will try an ultra-high-density OPTRELL mapping catheter to map electrical cycle length and voltage in people with persistent or permanent atrial fibrillation to better target ablation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Taipei Veterans General Hospital, Taiwan Government |
| Locations | 1 site (Taipei, Outside US) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | August 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | September 9, 2025 |
| Trial ID | NCT06960252 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 20 or older with symptomatic persistent or permanent AF who are refractory or intolerant to at least one Class I or III antiarrhythmic medication and can provide informed consent are ideal candidates.
✕Probably not a fit
Patients with an atrial or ventricular thrombus, severe renal insufficiency or dialysis, contrast allergy, pregnancy, inability to undergo X-ray, or those with paroxysmal AF are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study will use the OPTRELL ultra-high-density mapping catheter to obtain unipolar and bipolar voltage maps in sinus rhythm and cycle-length maps during atrial fibrillation in patients with non-paroxysmal AF. Investigators will compare mapped cycle-length drivers and areas of low voltage consistent with interstitial fibrosis to better characterize the atrial substrate. The protocol builds on prior multicenter CLM work showing benefit from targeted driver ablation and applies a new mapping catheter to refine substrate identification. The observational design focuses on mapping and characterization to inform potential targeted ablation strategies rather than randomizing treatments.
Why it matters
Potential benefit: If successful, this approach could enable more precise, patient-tailored ablation and reduce AF recurrence after the procedure.
How similar studies have gone: Previous multicenter CLM work between Taipei Veterans General Hospital and IRCCS San Donato showed targeted CLM driver-ablation improved arrhythmia-free outcomes, while applying the OPTRELL catheter in this setting represents a newer application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who sign the informed consent forms, and allow to be followed. 2. Symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication. 3. Patients with persistent/permanent AF (sustained beyond seven days, or lasting less than seven days but necessitating pharmacologic or electrical cardioversion). Persistent AF is defined as an AF episode which lasts longer than 7 days, Persistent AF which lasted longer than 12 months will be defined as long standing persistent AF. 4. Patients with age equal or greater than 20 years old regardless of gender. Exclusion Criteria: 1. The presence of an atrial or ventricular thrombus. 2. Patients who are allergic to or unsuitable for use with the contrast media. 3. Pregnant patients or patients who are unavailable to receive X-ray. 4. Patients with severe renal insufficiency. (Glomerular Filtration Rate \[GFR\] \< 15 mg/dl or under dialysis) 5. Patients had autonomic nervous system disorder (e.g. respiratory apnea). 6. Patients with age less than 20 years old or greater than 90 years old regardless of gender. 7. Contraindications to anticoagulation.
Where it's running
-
Taipei Veterans General Hospital
Taipei, Outside US, Taiwan Recruiting
Study contacts
- Study coordinator: Ting-Yung Chang, M.D.
- Email: tingyungchang@gmail.com
- Phone: 886-2-2875-7808
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation
This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.
-
Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation
This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.
-
Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF
This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes
This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.
-
AI-based cardiac analysis using 12-lead and 1-lead ECG
A clinician-facing pilot test to see if SmartECG-EF helps evaluate heart function using both 12-lead and single-lead ECGs in adults with heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.